<DOC>
	<DOCNO>NCT00784238</DOCNO>
	<brief_summary>The purpose study evaluate improvement efficacy paliperidone extended-release subjective well-being drug attitude participant , switch oral antipsychotic participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>Efficacy Study Paliperidone Evaluate Subjective Change Well-being Drug Attitude Schizophrenic Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-centric ( conducted one center ) , prospective ( study follow participant forward time ) , non-comparative study , participant schizophrenia . The study consist follow part : Screening ( , 14 day study commences Day 1 ) ; Acute Treatment phase ( 24 week ) ; Extension phase 1 ( 24 week ) , follow additional Extension phase 2 ( 48 week ) . Total study duration per participant 96 week . Efficacy primarily evaluate change Baseline Subjective Well-being Under Neuroleptic ( SWN-20 ) Scale score change Baseline Drug Attitude Inventory score . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants diagnose schizophrenia ( diagnosis criterion : Diagnostic Statistical Manual Mental Disorders , fourth edition [ DSMIV ] ) Participants need change antipsychotic drug another one follow reason among participant treat antipsychotic drug two week screeningLack efficacy , lack tolerance lack compliance Participants capable willing fill questionnaire Childbearing potential woman consent use consistently permissible contraception ( oral contraceptive , contraceptive injection , intrauterine device , double barrier method contraceptive patch ) Participants compliant selfmedication receive consistent help support Participants past history neuroleptic malignant syndrome ( NMS ) , allergy hypersensitivity risperidone paliperidone Participants take clozapine within one month screen Participants suspicious clinically significant risk include suicide aggressive behavior expect unable complete study ( base investigator 's judgment ) Participants severe preexist gastrointestinal narrowing ( pathologic iatrogenic ) participant swallow drug whole ( The study drug must chew , divide , melt grind impact study drug release profile ) Participants know suspected history ( 6 month longer ) substance dependence accord DSMIV criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Extended-release</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>R076477</keyword>
</DOC>